



## A MISSING PIECE TO YOUR COMPLEX CANCER PUZZLE





### ABOUT CUREMATCH

CureMatch's algorithmic cancer therapy matching and ranking service is unique in that it takes the tumor marker results from a patient's Next Generation Sequencing (NGS) Report and looks at **ALL** of the patient's mutations together, rather than individually. The data is then synthesized with curated clinical evidence and the use of AI-based algorithms; reporting out the best matched, ranked, and scored drug combinations to fight a patient's cancer.

### PATIENT-CENTERED (N-OF-1) APPROACH

Co-targeting multiple mutations, rather than the single drug, single target therapy approach, enables personalized drug combinations that oncologists can consider when optimizing each patient's individual treatment plan.



### BENEFITS OF CUREMATCH

- ✓ Customizes cancer treatments matched to target the biomarkers of a patient's individual cancer
- ✓ Helps address as many biomarkers as possible to fight a patient's cancer
- ✓ Helps avoid any potential unnecessary toxicities
- ✓ Helps reduce the extra financial burden of ineffective cancer therapies
- ✓ Helps improve chances and provides hope for a better outcome

### CUREMATCH STEPS:



Contact Us For More Information :

T: +1 (858) 284.0488 | F: +1 (858) 430.5813  
| [www.curematch.com](http://www.curematch.com)



# CUSTOMIZED ONCOLOGY REPORT

## CUREMATCH REPORT

CureMatch prioritizes customized cancer therapy options by matching, ranking, and scoring the best known and novel combinations of treatment based on the biology of the patient's individual tumor.



Patient's Name  
Medical Record #  
CureMatch ID  
Age  
Sex  
Program Version  
Report Date  
Diagnosis  
Sample Type


CM\_006262  
64  
female  
1.65 on 2023-01-06  
01/16/2023  
Carcinoma of unknown primary  
FoundationOne, Lymph Node; Caris

Thank you for choosing CureMatch®

This report provides a ranking of the top treatment options that are personalized for each individual patient, using the molecular profile of a patient's tumor and proprietary databases and algorithms developed by CureMatch.

### OVERVIEW

The highest molecularly matched options for 1, 2 and 3 drug therapies are shown below. The score is an indicator of the degree to which a given therapy option matches all clinically significant markers in a patient's molecular profile. The score itself is not a prediction of efficacy, % chance of response or survival. Therapy choice should be made by the physician considering all factors related to the patient's condition.




Note: The therapeutic options above may have alternative drug choices listed in Targeting Description table sections. Drugs are considered alternatives when they share analogous mechanisms of action, therapy type and impact on the score.


## CLINICAL EVIDENCE

The higher the matching score translated into significantly better response, progression-free survival and overall survival.

### Published Results from I-PREDICT Study: Metastatic, treatment refractory



Higher matching score (>50%) translated into significantly better response, progression-free survival and overall survival



## CUREMATCH THERAPY MATCHING SCORE

The CureMatch Therapy Matching Score represents the degree to which a given therapy addresses and co-targets the patient's molecular cancer biomarkers.

### TOP RANKED 3-DRUG COMBINATION THERAPIES

CureMatch Score	DRUGS	TARGETING DESCRIPTION	INDICATIONS & RECOMMENDATIONS	
			FDA	OFF-LABEL
73%	fam-trastuzumab deruxetecan-nxki	ERBB2 TOP1		✓
	pembrolizumab	TMB	✓	
	trametinib	KRAS via MAP2K1, MAP2K2 NF1 via MAP2K1, MAP2K2		✓
<b>Black-Box Warning</b> fam-trastuzumab deruxetecan-nxki: Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with EHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue EHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms. Exposure to EHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.				
<b>Examples of alternative drugs for pembrolizumab</b> dostarlimab-glyx, atezolizumab, avelumab, cemiplimab-rwc, durvalumab, nivolumab				
<b>Examples of alternative drugs for trametinib</b> binimetinib				
<b>Examples of existing clinical trials using matched drug combinations</b> While clinical trials using some of these drugs alone or in combination with other drugs exist, no clinical trials testing this exact association of drugs can be found.				
<b>Potential drug-drug interactions</b> There may be drug-drug interactions not listed here. Administering drug combinations is at the discretion of the physician.				

## INCLUDED IN CUREMATCH REPORT

- ✓ Standard-of-Care Therapy
- ✓ Immunotherapy
- ✓ Chemotherapy
- ✓ Hormone Therapy
- ✓ Exclusions and Warnings
- ✓ Clinical Rationale for Each Therapy Option
- ✓ Examples of Drug Alternatives
- ✓ Examples of **Clinical Trials** using Matched Therapies
- ✓ Black Box Warnings and Drug-Drug Interactions
- ✓ Physician's Selection Scored
- ✓ Combination, Dosing, and Report References

Contact Us For More Information :

T: +1 (858) 284.0488 | F: +1 (858) 430.5813  
| [www.curematch.com](http://www.curematch.com)

